Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Minerva Biotechnologies (United States)

minervabio.comROR OpenAlex
Research works
30
▼ 28% vs 2018-21
Citations
382
12.6 per fractional work
Top-10% rate
8.5%
all institutions 10.0%
Open access
20%
world 40%
International
6%
world 18%
Minerva Biotechnologies (United States)

Not ranked overall: Minerva Biotechnologies (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Minerva Biotechnologies (United States) work in?

In all years, 46% of research at Minerva Biotechnologies (United States) is in Health Sciences, 45% in Life Sciences. Its largest fields are Medicine (46%), Biochemistry, Genetics and Molecular Biology (42%), Materials Science (6%). It does 2.2× the world's share of Life Sciences.

Health Sciences: 14 fractional works · 46.2% of its workMedicine: 14 fractional works · 45.7% of its workOncology: 8 fractional works · 27.9% of its workRadiology, Nuclear Medicine and Imaging: 4 fractional works · 14.8% of its workRehabilitation: 0 fractional works · 1.2% of its workOrthopedics and Sports Medicine: 0 fractional works · 0.6% of its workSurgery: 0 fractional works · 0.6% of its workGenetics: 0 fractional works · 0.4% of its workPhysiology: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.6% of its workOccupational Therapy: 0 fractional works · 0.6% of its workLife Sciences: 14 fractional works · 45.1% of its workBiochemistry, Genetics and Molecular Biology: 13 fractional works · 41.7% of its workMolecular Biology: 8 fractional works · 25.2% of its workBiotechnology: 4 fractional works · 11.8% of its workCancer Research: 1 fractional works · 3.4% of its workCell Biology: 0 fractional works · 1.1% of its workMolecular Medicine: 0 fractional works · 0.3% of its workImmunology and Microbiology: 1 fractional works · 2.5% of its workImmunology: 1 fractional works · 2.5% of its workAgricultural and Biological Sciences: 0 fractional works · 0.6% of its workFood Science: 0 fractional works · 0.3% of its workInsect Science: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workNeuroscience: 0 fractional works · 0.4% of its workDevelopmental Neuroscience: 0 fractional works · 0.4% of its workPhysical Sciences: 3 fractional works · 8.7% of its workMaterials Science: 2 fractional works · 6.3% of its workBiomaterials: 2 fractional works · 5.2% of its workElectronic, Optical and Magnetic Materials: 0 fractional works · 0.6% of its workMaterials Chemistry: 0 fractional works · 0.6% of its workEngineering: 1 fractional works · 2.1% of its workAerospace Engineering: 0 fractional works · 1.1% of its workElectrical and Electronic Engineering: 0 fractional works · 0.3% of its workIndustrial and Manufacturing Engineering: 0 fractional works · 0.3% of its workMedia Technology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEnvironmental Science: 0 fractional works · 0.3% of its workPollution: 0 fractional works · 0.3% of its workALL ITS WORKMinervaBiotechnologies…30fractional works, all years
Life Sciences45%Physical Sciences9%Health Sciences46%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 9 fields, with their numbers
    1. Medicine1445.7%
    2. Health Professions00.6%
    1. Biochemistry, Genetics and Molecular Biology1341.7%
    2. Immunology and Microbiology12.5%
    3. Agricultural and Biological Sciences00.6%
    4. Neuroscience00.4%
    1. Materials Science26.3%
    2. Engineering12.1%
    3. Environmental Science00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Minerva Biotechnologies (United States)?

Ranked on the quality score, Cynthia Carol Bamdad, Benoit J. Smagghe and Tyler E. Swanson lead among researchers whose main affiliation is Minerva Biotechnologies (United States).

  1. 1 Cynthia Carol Bamdad United States · #2,087,814 worldwide 1.3k citations · 42 works
  2. 2 Benoit J. Smagghe United States · #2,570,989 worldwide 784 citations · 44 works
  3. 3 Tyler E. Swanson United States · #3,108,006 worldwide 40 citations · 15 works
  4. 4 Trevor J. Grant United States · #3,341,919 worldwide 74 citations · 34 works
  5. 5 Scott T. Moe United States · #3,631,661 worldwide 528 citations · 32 works
All ranked researchers at Minerva Biotechnologies (United States)

What are the most cited papers from Minerva Biotechnologies (United States)?

The most cited paper from Minerva Biotechnologies (United States) is "MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells" (Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al., 2009), with 96 citations. Next come "MUC1* Mediates the Growth of Human Pluripotent Stem Cells" (78) and "A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells" (75).

Most cited papers
#PaperReleasedCitations
1 MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells Shawn P. Fessler, Mark T. Wotkowicz, Sanjeev K. Mahanta et al. · Breast Cancer Research and Treatment 4 May 2009 96
2 MUC1* Mediates the Growth of Human Pluripotent Stem Cells Sherry T. Hikita, Kenneth S. Kosik, Dennis Clegg et al. · PLoS ONE Open access 2 Oct 2008 78
3 A Minimal Fragment of MUC1 Mediates Growth of Cancer Cells Sanjeev K. Mahanta, Shawn P. Fessler, Jae-Hong Park et al. · PLoS ONE Open access 29 Apr 2008 75
4 Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Thomas N. Seyfried, Jeremy Marsh, Laura M. Shelton et al. · Epilepsy Research Open access Sep 2011 69
5 Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment Steve Griffiths, Michelle A. Cormier, Aled Clayton et al. · Proteomes Open access 8 Oct 2017 52
All 17 most cited papers, with filters and sorting

Which keywords describe research at Minerva Biotechnologies (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Immunotherapy, Tumor Regression, Cancer Immunotherapy, Glycosylation, CAR T Cells, Chimeric Antigen Receptor, Monoclonal Antibodies and Tumor Targeting.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 28 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 28 words, with their numbers
  1. Immunotherapy10▲ 51×3 topics
  2. Tumor Regression10▲ 375×2 topics
  3. Cancer Immunotherapy7▲ 161×2 topics
  4. Glycosylation6▲ 97×2 topics
  5. CAR T Cells6▲ 482×1 topic
  6. Chimeric Antigen Receptor6▲ 482×1 topic
  7. Monoclonal Antibodies5▲ 109×2 topics
  8. Tumor Targeting5▲ 118×2 topics
  9. Fc Receptors4▲ 148×1 topic
  10. Therapeutic Antibodies4▲ 115×1 topic
  11. Arginine Deprivation4▲ 269×1 topic
  12. Bacterial Therapy4▲ 269×1 topic
  13. Epithelial-Mesenchymal Transition3▲ 114×2 topics
  14. Cancer2▲ 5.9×4 topics
  15. Cancer Therapy2▲ 12×5 topics
  16. Metastasis Suppressors2▲ 1712×1 topic
  17. NDRG Family2▲ 1712×1 topic
  18. Immune System2▲ 21×2 topics
  19. Therapeutics2▲ 49×2 topics
  20. Glycans2▲ 81×1 topic
  21. Mucins2▲ 81×1 topic
  22. Biomedical Applications2▲ 5.8×6 topics
  23. Drug Delivery2▲ 12×5 topics
  24. Tumor Microenvironment2▲ 16×3 topics
  25. Nanoparticles1▲ 3.3×2 topics
  26. Nanocarriers1▲ 88×1 topic
  27. Surface Engineering1▲ 34×1 topic
  28. Angiogenesis1▲ 8.2×2 topics

Which research topics does Minerva Biotechnologies (United States) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Mechanisms of cancer metastasis, Cancer Research and Treatments and Monoclonal and Polyclonal Antibodies Research.

CAR-T cell therapy resea…2CAR-T cell therapy research: 2 fractional worksMechanisms of cancer met…2Mechanisms of cancer metastasis: 2 fractional worksCancer Research and Treatments: 1 fractional worksMonoclonal and Polyclonal Antibodies Research: 1 fractional worksCancer, Hypoxia, and Metabolism: 1 fractional worksCongenital heart defects…0Congenital heart defects research: 0 fractional worksImmunotherapy and Immune Responses: 0 fractional worksGlycosylation and Glycoproteins Research: 0 fractional worksChromatin Remodeling and Cancer: 0 fractional worksBiochemical and Molecular Research: 0 fractional works
OncologyMolecular BiologyBiotechnologyRadiology, Nuclear Medicine and Imaging2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 2 works
  2. 2 Mechanisms of cancer metastasis Molecular Biology 2 works
  3. 3 Cancer Research and Treatments Biotechnology 1 works
  4. 4 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  5. 5 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
  6. 6 Congenital heart defects research Molecular Biology 0 works
  7. 7 Immunotherapy and Immune Responses Immunology 0 works
  8. 8 Glycosylation and Glycoproteins Research Molecular Biology 0 works
  9. 9 Chromatin Remodeling and Cancer Molecular Biology 0 works
  10. 10 Biochemical and Molecular Research Molecular Biology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available19.7%not open80.3%

World: 40% of research is openly available.

with international co-authors5.5%domestic only94.5%

World: 18% is written across borders.

How has Minerva Biotechnologies (United States)'s research output changed?

Output in 2022-2025 was 28% lower than in 2018-2021.

still counting20052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Minerva Biotechnologies (United States) as a percentage of every work published that year, 0.000051% in 2024.

still counting0.000050%0.00010%Minerva Biotechnologies (United States)0.000037% in 202520102020

Fractional works of Minerva Biotechnologies (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Minerva Biotechnologies (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.